Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public

By Trey Thoelcke Published Aug 13, 9:35AM EDT

Quick Read

LTGO priced its IPO at $18, opened at $21, and raised nearly $350 million from an oversubscribed offering.
LTG-001 delivered 50% greater pain relief than hydrocodone in a 343-patient trial, positioning it for a first-ever opioid-free label claim.
Phase 3 trials launching in 2026 with 2027 readouts will test whether Latigo's Nav1.8 pipeline can replicate Vertex's suzetrigine success.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public — © 24/7 Wall St.

Latigo Biotherapeutics (NASDAQ:LTGO) arrived on public markets with the kind of reception biotech bankers dream about. The Thousand Oaks, California, clinical-stage developer priced its IPO at $18 per share and opened at $21, raising nearly $350 million after an oversubscribed book. Shares recently changed hands at $19.38. That is up 6.2% from the $18.25 close on August 7 and 4.62% higher in the latest session.

The Non-Opioid Pain Thesis

Latigo is a bet that selective Nav1.8 inhibition can capture a meaningful share of a U.S. pain market estimated at 250 million prescriptions annually. The S-1 describes the company as a “clinical-stage biopharmaceutical focused on non-opioid pain medicines” with three assets:

LTG-001, a Nav1.8 inhibitor for acute pain
LTG-321, a Nav1.8 inhibitor for chronic musculoskeletal pain
LTG-418, a next-generation Nav1.8 inhibitor in preclinical development

In a randomized, placebo-controlled abdominoplasty trial in 343 patients across four U.S. centers, high-dose oral LTG-001 hit its primary endpoint with a 62.1-point SPID48 improvement versus placebo and approximately 50% greater analgesic effect than the active hydrocodone/acetaminophen comparator arm. The low-dose arm delivered an SPID48 of 37.8 (p=0.003), comparable to the opioid comparator. Latigo believes LTG-001 could become the “first systemic analgesic to receive” an opioid-free label claim.

Preclinical pharmacology supports the peripheral-only story. The filing reports a 42:1 nerve-to-brain ratio and states that the drug is “believed not to carry dependency risk.”

Cash Burn and Going-Concern Language

The S-1 discloses cash and equivalents of $69.4 million as of December 31, 2025. That compares with net losses of $109.2 million in 2025 and $61.2 million in 2024. Operating cash outflows reached $97.6 million last year, up from $51.0 million. The auditor flagged “substantial doubt regarding ability to continue as going concern.” The IPO proceeds materially reset that runway.

What to Watch Next

Latigo plans to initiate a Phase 3 bunionectomy trial and an open-label acute pain safety study in the second half of 2026, with topline results expected in the second half of 2027. In parallel, LTG-321 has entered a Phase 2 proof-of-concept trial in approximately 120 osteoarthritis patients with WOMAC pain as the primary endpoint, also reading out in the second half of 2027.

Aggregated sentiment currently scores 65.19, tilting bullish with low confidence, reflecting a thin post-IPO trading history. The Vertex Pharmaceuticals suzetrigine approval established the Nav1.8 template. Latigo now has capital, clean data, and roughly a year until the next pivotal readouts will test whether that template can be replicated.

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google

About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.